Acorah Software Products - Accounts Production 16.2.850 false true true 31 July 2023 1 August 2022 false 1 August 2023 31 July 2024 31 July 2024 08143706 Mr Philip John Royston Mcsweeney Dr Michael James Thomas Brooks Dr Philip Carr Ashworth iso4217:GBP iso4217:EUR iso4217:USD xbrli:shares xbrli:pure xbrli:pure 08143706 frs-core:CurrentFinancialInstruments frs-core:WithinOneYear 2024-07-31 08143706 frs-core:Non-currentFinancialInstruments frs-core:BetweenOneFiveYears 2024-07-31 08143706 2023-07-31 08143706 2024-07-31 08143706 2023-08-01 2024-07-31 08143706 frs-core:CurrentFinancialInstruments 2024-07-31 08143706 frs-core:Non-currentFinancialInstruments 2024-07-31 08143706 frs-core:ComputerEquipment 2024-07-31 08143706 frs-core:ComputerEquipment 2023-08-01 2024-07-31 08143706 frs-core:ComputerEquipment 2023-07-31 08143706 frs-core:SharePremium 2024-07-31 08143706 frs-core:ShareCapital 2024-07-31 08143706 frs-core:RetainedEarningsAccumulatedLosses 2024-07-31 08143706 frs-bus:PrivateLimitedCompanyLtd 2023-08-01 2024-07-31 08143706 frs-bus:FilletedAccounts 2023-08-01 2024-07-31 08143706 frs-bus:SmallEntities 2023-08-01 2024-07-31 08143706 frs-bus:AuditExempt-NoAccountantsReport 2023-08-01 2024-07-31 08143706 frs-bus:SmallCompaniesRegimeForAccounts 2023-08-01 2024-07-31 08143706 frs-bus:OrdinaryShareClass1 2023-08-01 2024-07-31 08143706 frs-bus:OrdinaryShareClass1 2024-07-31 08143706 frs-core:FurtherSpecificReserve1ComponentTotalEquity 2024-07-31 08143706 frs-bus:Director1 2023-08-01 2024-07-31 08143706 frs-bus:Director2 2023-08-01 2024-07-31 08143706 frs-bus:Director3 2023-08-01 2024-07-31 08143706 frs-countries:EnglandWales 2023-08-01 2024-07-31 08143706 frs-core:CurrentFinancialInstruments frs-core:WithinOneYear 2023-07-31 08143706 frs-core:Non-currentFinancialInstruments frs-core:BetweenOneFiveYears 2023-07-31 08143706 2022-07-31 08143706 2023-07-31 08143706 2022-08-01 2023-07-31 08143706 frs-core:CurrentFinancialInstruments 2023-07-31 08143706 frs-core:Non-currentFinancialInstruments 2023-07-31 08143706 frs-core:SharePremium 2023-07-31 08143706 frs-core:ShareCapital 2023-07-31 08143706 frs-core:RetainedEarningsAccumulatedLosses 2023-07-31 08143706 frs-bus:OrdinaryShareClass1 2022-08-01 2023-07-31 08143706 frs-core:FurtherSpecificReserve1ComponentTotalEquity 2023-07-31
Registered number: 08143706
Patientsource Limited
Unaudited Financial Statements
For The Year Ended 31 July 2024
Max Accountants Ltd
Ketton Suite
The King Centre
Oakham
Rutland
LE15 7WD
Contents
Page
Balance Sheet 1—2
Notes to the Financial Statements 3—5
Page 1
Balance Sheet
Registered number: 08143706
2024 2023
Notes £ £ £ £
FIXED ASSETS
Tangible Assets 4 29 1,760
29 1,760
CURRENT ASSETS
Debtors 5 269,156 155,990
Cash at bank and in hand 82,260 166,427
351,416 322,417
Creditors: Amounts Falling Due Within One Year 6 (365,705 ) (249,072 )
NET CURRENT ASSETS (LIABILITIES) (14,289 ) 73,345
TOTAL ASSETS LESS CURRENT LIABILITIES (14,260 ) 75,105
Creditors: Amounts Falling Due After More Than One Year 7 (10,289 ) (18,452 )
NET (LIABILITIES)/ASSETS (24,549 ) 56,653
CAPITAL AND RESERVES
Called up share capital 9 526 526
Share premium account 1,999,152 1,999,152
Fair value reserve 133,831 344,479
Profit and Loss Account (2,158,058 ) (2,287,504 )
SHAREHOLDERS' FUNDS (24,549) 56,653
Page 1
Page 2
For the year ending 31 July 2024 the company was entitled to exemption from audit under section 477 of the Companies Act 2006 relating to small companies.
The members have not required the company to obtain an audit in accordance with section 476 of the Companies Act 2006.
The directors acknowledge their responsibilities for complying with the requirements of the Act with respect to accounting records and the preparation of accounts.
These accounts have been prepared and delivered in accordance with the provisions applicable to companies subject to the small companies regime.
The company has taken advantage of section 444(1) of the Companies Act 2006 and opted not to deliver to the registrar a copy of the company's Profit and Loss Account.
On behalf of the board
Dr Philip Carr Ashworth
Director
1 April 2025
The notes on pages 3 to 5 form part of these financial statements.
Page 2
Page 3
Notes to the Financial Statements
1. General Information
Patientsource Limited is a private company, limited by shares, incorporated in England & Wales, registered number 08143706 . The registered office is Blenheim House Denny End Road, Waterbeach, Cambridge, Cambridgeshire, CB25 9PB.
2. Accounting Policies
2.1. Basis of Preparation of Financial Statements
The financial statements have been prepared under the historical cost convention and in accordance with Financial Reporting Standard 102 section 1A Small Entities "The Financial Reporting Standard applicable in the UK and Republic of Ireland" and the Companies Act 2006.
The financial statements are prepared in sterling, which is the functional currency of the company. Monetary amounts in these financial statements are rounded to the nearest £.
2.2. Going Concern Disclosure
The directors have not identified any material uncertainties related to events or conditions that may cast significant doubt about the company's ability to continue as a going concern. Therefore the financial statements have been prepared on a going concern basis which assumes the Company will continue in operational existence for the foreseeable future. 
The Company is involved in research and development activities and is working towards achieving a sustainable revenue generating activity. The directors have considered the basis of the financial statements and are satisfied that a combination of business growth and further investment commitments will enable the Company to meet its liabilities as they fall due.
2.3. Turnover
Turnover is recognised to the extent that it is probable that the economic benefits will flow to the Company and the turnover can be reliably measured. Turnover is measured as the fair value of the consideration received or receivable, excluding discounts, rebates, value added tax and other sales taxes.
2.4. Tangible Fixed Assets and Depreciation
Tangible fixed assets are measured at cost less accumulated depreciation and any accumulated impairment losses. Depreciation is provided at rates calculated to write off the cost of the fixed assets, less their estimated residual value, over their expected useful lives on the following bases:
Computer Equipment Straight line over 3 years
2.5. Cash and Cash Equivalents
Cash and cash equivalents are basic financial assets and include cash in hand and deposits held at call with banks, other short-term highly liquid investments that mature in no more than three months from the date of acquisition and are readily convertible to a known amount of cash with insignificant risk of change in value, and bank overdrafts.
2.6. Financial Instruments
The company has elected to apply the provisions of Section 11 ‘Basic Financial Instruments’ and Section 12 ‘Other Financial Instruments Issues’ of FRS 102 to all of its financial instruments.
Financial instruments are recognised in the company's balance sheet when the company becomes party to the contractual provisions of the instrument.
Basic financial assets
Basic financial assets, which include debtors and bank balances, are measured at transaction price including transaction costs.
Classification of financial liabilities
Financial liabilities and equity instruments are classified according to the substance of the contractual arrangements entered into. An equity instrument is any contract that evidences a residual interest in the assets of the company after deducting all of its liabilities.
Basic financial liabilities
Basic financial liabilities, including creditors, are recognised at transaction price including transaction costs.
Trade creditors are obligations to pay for goods or services that have been acquired in the ordinary course of business from suppliers. Amounts payable are classified as current liabilities.
Page 3
Page 4
2.7. Foreign Currencies
Monetary assets and liabilities in foreign currencies are translated into sterling at the rates of exchange ruling at the balance sheet date. Transactions in foreign currencies are translated into sterling at the rate ruling on the date of the transaction. Exchange differences are taken into account in arriving at the profit / loss before taxation.
2.8. Taxation
Tax is recognised in profit or loss except that a charge is attributable to an item of income and expense recognised as other comphrehensive income or to an item recognised directly in equity is also recognised in other comphrehensive income or directly in equity respectively.
The current income tax charge is calculated on the basis of tax rates and laws that have been enacted or substantively enacted by the balance sheet date in the countries where the company operates and generates income.
2.9. Pensions
The company operates a defined pension contribution scheme. Contributions are charged to the profit and loss account as they become payable in accordance with the rules of the scheme.
2.10. Research and development
The company operates an equity-settled, share-based compensation plan, under which the entity received services from employees as consideration for equity instruments (options) of the entity. The fair value of the employee services received is measured by reference to the estimated fair value at the grant date of equity instruments granted and is recognised as an expense over the vesting period. The estimated fair value of the option granted is calculated using the Black Scholes option pricing model. The total amount expensed is recognised over the vesting period, which is the period over which all of the specified vesting conditions are to be satisfied. 
The proceeds received net of any directly attributable transaction costs are credited to share capital (nominal value) and share premium when the options are exercised. 
2.11. Share-based payments
The company operates an equity-settled, share-based compensation plan, under which the entity received services from employees as consideration for equity instruments (options) of the entity. The fair value of the employee services received is measured by reference to the estimated fair value at the grant date of equity instruments granted and is recognised as an expense over the vesting period. The estimated fair value of the option granted is calculated using the Black Scholes option pricing model. The total amount expensed is recognised over the vesting period, which is the period over which all of the specified vesting conditions are to be satisfied. 
The proceeds received net of any directly attributable transaction costs are credited to share capital (nominal value) and share premium when the options are exercised. 
3. Average Number of Employees
Average number of employees, including directors, during the year was: 8 (2023: 7)
8 7
4. Tangible Assets
Computer Equipment
£
Cost
As at 1 August 2023 8,971
As at 31 July 2024 8,971
Depreciation
As at 1 August 2023 7,211
Provided during the period 1,731
As at 31 July 2024 8,942
Net Book Value
As at 31 July 2024 29
As at 1 August 2023 1,760
Page 4
Page 5
5. Debtors
2024 2023
£ £
Due within one year
Trade debtors 192,990 25,972
Prepayments and accrued income 10,106 14,313
Other debtors 10 945
Corporation tax recoverable assets 65,843 114,553
Directors' loan accounts 207 207
269,156 155,990
6. Creditors: Amounts Falling Due Within One Year
2024 2023
£ £
Trade creditors 15,754 6,771
Bank loans and overdrafts 8,778 10,648
Other taxes and social security 14,036 11,869
VAT 40,802 41,020
Other creditors 123,046 2,286
Accruals and deferred income 163,289 176,478
365,705 249,072
7. Creditors: Amounts Falling Due After More Than One Year
2024 2023
£ £
Bank loans 10,289 18,452
8. Loans
An analysis of the maturity of loans is given below:
2024 2023
£ £
Amounts falling due within one year or on demand:
Bank loans 8,778 10,648
2024 2023
£ £
Amounts falling due between one and five years:
Bank loans 10,289 18,452
9. Share Capital
2024 2023
Allotted, called up and fully paid £ £
1,890,696 Ordinary Shares of £ 0.000278 each 526 526
Page 5